Stem cell biotechnology company and Accelerating Australia consortium member, Orthocell has treated its first patient in a clinical trial of their Ortho-ATI® injection designed to treat shoulder injuries.
Specifically designed for the treatment of rotator cuff tendinopathy and shoulder tears, the results from injection of Ortho-ATI® will be compared to the effectiveness of corticosteroid injections and all expectations are positive;
“Demonstrating the efficacy of Ortho-ATI® for the treatment of rotator cuff tendinopathy is an important element of our product development and partnering strategy. We expect results to show Ortho-ATI® is a durable and effective treatment for degenerate shoulder injuries,” says Orthocell managing director Paul Anderson.
Taking huge strides in their development recently, Orthocell also reported positive safety and tolerability results for their Celgro® collagen membrane being used to treat cartiliage defects in the hip joint. Even more impressive, the biotech company announced in May this year that the TGA had included their Ortho-ACI® on the Australian Register of Therapeutic Goods.
Ortho-ATI® is available in Australia, New Zealand, and Hong Kong with regulatory oversight for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs.